Navigating the drug pricing debate



​When the Trump administration introduced a ‘blueprint’ to lower drug prices in May, the pharmaceutical industry breathed a sigh of relief. Andy Acker and Ethan Lovell, Portfolio Managers of the Global Life Sciences strategy, discuss.


When the Trump administration introduced a ‘blueprint’ to lower drug prices in May, the pharmaceutical industry breathed a sigh of relief. The proposal excluded recommendations such as allowing the government to negotiate drug prices directly with manufacturers or importing lower-cost prescription drugs from abroad, each of which could have caused significant disruption.

But the reprieve did not last long. In late June, announced it was buying PillPack, a mail-order pharmacy licenced to ship prescriptions in 49 states. Less than two weeks later, Pfizer raised prices on dozens of drugs – only to backtrack and postpone the hikes after President Trump criticised the move in a sharply worded tweet. Since then, other companies have also delayed price increases or even lowered prices.

In short, scrutiny over drug pricing continues, with the potential to intensify as we approach the US midterm elections. However, we think any potential reforms could take years to implement, and the impact for most companies should be moderate. Meanwhile, innovation within the sector remains high, leading to transformational therapies. With that in mind, we believe investors should be mindful of these key trends going forward.

Improving multiples

Given the uncertainty around drug pricing, biotechnology and pharmaceutical stocks have lagged the MSCI World Health Care Index, falling 1.0% and 2.2% respectively during the first half of 2018, while the benchmark gained 1.9%. However, we believe the underperformance has helped make valuations within these categories more attractive, especially in light of continued innovation.

Indeed, in April, late-stage clinical trial data showed that one lead immuno-oncology drug, in combination with chemotherapy, cut the risk of death for patients with advanced non-small cell lung cancer by 51%. We feel this represents a revolutionary advance for the leading cause of cancer death in the world. It also demonstrates both the clinical and commercial potential of these drugs, which harness the body’s immune system to attack and kill cancer cells. Immuno-oncology agents reached US$10 billion in sales in 2017, and we expect the number could exceed US$15 billion this year, with the potential to go much higher in the future.

A focus on value

The market could start to appreciate this innovation as the focus on value within the healthcare system intensifies. Last month, the US Food and Drug Administration (FDA) released guidance about how manufacturers can appropriately communicate a drug’s efficacy when negotiating so-called value-based contracts with payers. These contracts aim to tie reimbursement decisions to the overall treatments, an approach that is gaining ground in the US and select other countries. As Scott Gottleib, FDA commissioner, said in an adjoining statement: “Prices should be able to adjust to reflect the value in how medicines are prescribed and the outcomes they deliver, to control rising spending and reduce the burden of drug costs for consumers.” Companies whose therapies improve upon the current standard of care may have wider latitude to price attractively and secure reimbursement. For others, the stakes are rising.

Supply chain pressures

Members of the drug supply chain – distributors, pharmacy benefit managers and pharmacies – may also start to feel pricing pressure. Rebates and discounts paid by drug makers to the supply chain are often pointed to as one reason for rising drug prices. The discounts are calculated as a percentage of a drug’s list price, so the higher the price, the fatter the payout.

Trump’s blueprint proposes changing the incentive structure for rebates, including passing on some of the financial benefit directly to consumers. If regulators fail to make an impact, Amazon could eventually achieve a similar goal with its entry into drug distribution. As Amazon’s CEO, Jeff Bezos, famously quipped, “Your margin is my opportunity”. Either way, we expect that the supply chain could get squeezed. The market seems to agree: for the first half of the year healthcare distributors, as a sub-sector, declined by almost 10%.

The recent divergence in performance between innovators and the drug supply chain could continue in healthcare, underscoring why we think it is critical for investors to focus on fundamentals and understand the nuances when approaching the sector.


These are the views of the individuals at the time of writing and may differ from the views of other individuals/teams at Janus Henderson Investors. Any sectors, indices and securities mentioned within this article do not constitute or form any part of any offer or solicitation to buy or sell them.

Dit zijn de visies van de auteur op het moment van publicatie en die kunnen afwijken van de visies van andere personen of teams bij Janus Henderson Investors. De genoemde effecten, fondsen, sectoren en indices in dit artikel vormen geen (deel van een) aanbod of verzoek om die effecten te kopen of te verkopen.

Resultaten behaald in het verleden vormen geen garantie voor de toekomst. Alle performancegegevens omvatten inkomsten- en kapitaalwinsten of verliezen maar geen doorlopende kosten en andere fondsuitgaven.

De informatie in dit artikel mag niet worden beschouwd als een beleggingsadvies.

Voor promotiedoeleinden.

Belangrijke informatie

Lees de volgende belangrijke informatie over fondsen die vermeld worden in dit artikel.

Janus Henderson Global Life Sciences Fund

For institutional/ sophisticated investors / accredited investors qualified distributors use only.

All content in this document is for information or general use only and is not specific to any individual client requirements. The information contained in this document is referential and may not be construed as an offer, invitation or recommendation or investment advice, nor should be taken as a basis to take (or stop taking) any decision.

Janus Henderson Capital Funds Plc is a UCITS established under Irish law, with segregated liability between funds. Investors are warned that they should only make their investments based on the most recent Prospectus which contains information about fees, expenses and risks, which is available from all distributors and paying agents, it should be read carefully. An investment in the fund may not be suitable for all investors and is not available to all investors in all jurisdictions; it is not available to US persons.  Past performance is not indicative of future results. The rate of return may vary and the principal value of an investment will fluctuate due to market and foreign exchange movements.  Shares, if redeemed, may be worth more or less than their original cost.

Janus Henderson Group plc and its subsidiaries are not responsible for any unlawful distribution of this document to any third parties, in whole or in part, or for information reconstructed from this document and do not guarantee that the information supplied is accurate, complete, or timely, or make any warranties with regards to the results obtained from its use. As with all investments, there are inherent risks that each individual should address.

The distribution of this document or the information contained in it may be restricted by law and may not be used in any jurisdiction or any circumstances in which its use would be unlawful.

Issued in Europe by Janus Capital International Limited (“JCIL”), authorised and regulated by the U.K. Financial Conduct Authority. Janus Capital International Limited (“JCIL”) is an entity registered and operating under the laws of the United Kingdom and Janus Capital Funds plc. is registered under the legislation of Ireland.

The extract prospectus (edition for Switzerland), the articles of incorporation, the extract annual and semi-annual report, in German, can be obtained free of charge from the representative in Switzerland: First Independent Fund Services Ltd (“FIFS”), Klausstrasse 33, CH-8008 Zurich, Switzerland, tel: +41 44 206 16 40, fax: +41 44 206 16 41, web: The Swiss paying agent is: Banque Cantonale de Genève, 17, quai de l’Ile, CH-1204 Geneva. The last share prices can be found on For Qualified investors, institutional, wholesale client use only. Outside of Switzerland, this document is for professional use only. Not for onward distribution.

This presentation is strictly private and confidential and may not be reproduced or used for any purpose other than evaluation of a potential investment in Janus Capital International Limited’s products or the procurement of its services by the recipient of this presentation or provided to any person or entity other than the recipient of this presentation.

We may record telephone calls for our mutual protection, to improve customer service and for regulatory record keeping purposes.

Janus Capital Management LLC serves as investment adviser. Janus, Intech and Perkins are registered trademarks of Janus International Holding LLC. © Janus International Holding LLC. For more information or to locate your country’s Janus representative contact information, please visit

Specifieke risico's

  • ​Het Fonds streeft ernaar het risico te beperken door te beleggen in verschillende bedrijven en segmenten van de life science-sector. Het Fonds is mogelijk echter minder gespreid dan andere beleggingsproducten en het verlies kan verhoudingsgewijs groter zijn als een bepaalde belegging in waarde daalt.
  • Het Fonds kan genoteerd zijn in een andere valuta dan de aandelenklasse van uw belegging. De waarde van uw aandelen kan stijgen of dalen als gevolg van wisselkoersbewegingen tussen valuta’s.
  • ​Het Fonds kan beleggingen bezitten die zijn genoteerd in andere valuta's dan de basisvaluta van het Fonds. Bewegingen van wisselkoersen kunnen het Fonds blootstellen aan verliezen ongeacht de performance van de belegging.
  • Het Fonds maakt gebruik van speciale financiële afgeleide instrumenten die winsten en verliezen kunnen opleveren die ruim boven de oorspronkelijke kosten van deze afgeleide instrumenten liggen. Daarmee verhogen ze het risico aanzienlijk. We proberen dit risico te beperken door middel van een robuust risicobeheerproces dat erop is gericht het maximale potentiële verlies te beperken. Het gebruik van deze instrumenten brengt ook ander risico's met zich mee, met name tegenpartijrisico, het risico voor elke partij in een contract dat de andere partij zijn contractuele verplichtingen niet nakomt.
  • De beleggingen van het Fonds zijn gericht op life science-bedrijven. Veranderingen in de regelgeving of de verstrekking van subsidies, of veranderingen in technologie kunnen van invloed zijn op de waarde van de beleggingen van het Fonds.
  • De waarde van beleggingen in het Fonds en het rendement uit deze beleggingen kan stijgen of dalen. Het kan zo zijn dat het Fonds zijn beleggingsdoelstellingen niet haalt.
  • Kleinere of nieuwere bedrijven hebben een groter potentieel voor risico en rendement. Deze beleggingen kunnen volatiel zijn of zijn moeilijk te kopen of verkopen.



Investeer in de kracht van disruptie

Veranderingen volgen elkaar nu sneller dan ooit op. Disruptie wordt gevoeld in verschillende industrieën en regio’s en is daarmee een onderscheidende factor in de langetermijnperformance van beleggingsportefeuilles. Er zijn aantrekkelijke kansen, maar ook aanzienlijke risico’s voor de ontwrichte industrieën.

Gerelateerde fondsen